GOVX · XBRL financial data

GeoVax Labs financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (GOVX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	2,444	15,554	9,123	20,721	23,714	18,122
General and administrative	2,196	3,577	4,987	6,022	5,385	6,007
Total operating expenses	4,640	19,131	14,110	26,743	29,099	24,128
Operating income (loss)	(2,817)	(18,746)	(14,029)	(26,743)	(25,144)	(21,639)
Interest income	2	5	7	776	173	174
Interest expense	144	1	0	0	21	0
Income tax expense (benefit)	0	0	—	—	—	0
Net income (loss)	(2,958)	(18,570)	(14,021)	(25,967)	(24,992)	(21,465)
Earnings per share, basic USD per share	—	(3.04)	(0.83)	(14.29)	(4.82)	(22.40)
Weighted average shares, basic thousands of shares	—	6,100	16,973	1,817	5,187	958

† Share count changed about 1/12 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (GOVX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	9,884	11,424	27,613	6,453	5,507	3,086
Accounts receivable	—	—	—	0	659	0
Prepaid and other current assets	169	156	1,326	1,433	1,769	2,229
Total current assets	10,235	11,629	28,939	7,886	7,935	5,315
Property and equipment, net	148	157	235	210	150	109
Right-of-use asset	—	—	—	—	0	831
Total assets	10,394	11,797	31,348	9,283	8,156	6,342
Accounts payable	268	2,058	1,748	2,803	1,850	791
Accrued liabilities	359	3,378	3,000	717	1,258	883
Total current liabilities	810	5,435	4,748	3,520	3,107	1,937
Lease liability, non-current	—	—	—	—	0	580
Total liabilities	825	7,435	4,748	—	3,107	2,517
Accumulated deficit	(45,806)	(64,376)	(78,397)	(104,364)	(129,356)	(150,821)
Total stockholders' equity	9,569	4,362	26,600	5,763	5,049	3,825
Total liabilities and equity	10,394	11,797	31,348	9,283	8,156	6,342
Common shares outstanding (cover page) thousands of shares	6,315	7,089	26,335	2,172	13,839	2,893

† Share count changed about 1/12 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (GOVX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(2,958)	(18,570)	(14,021)	(25,967)	(24,992)	(21,465)
Stock-based compensation	64	370	902	1,075	529	1,115
Depreciation and amortization	20	39	56	74	95	69
Net cash from operating activities	(2,751)	(11,196)	(19,030)	(25,174)	(24,676)	(21,474)
Purchases of property and equipment	157	48	134	49	21	28
Net cash from investing activities	(157)	(48)	(134)	(49)	(21)	(28)
Net cash from financing activities	12,508	12,784	35,353	4,062	23,751	19,080
Net change in cash	9,600	1,540	16,189	(21,160)	(946)	(2,421)

† Share count changed about 1/12 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
GeoVax Labs	3,143	not reported	(3,658)*	7.4M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
Earth Science Tech	631	9,026	707	287.6M	—	Q1 FY27 10-QJun 30, 2026
Edesa Biotech	10,300	not reported	(3,083)*	9.6M	3.3 quarters	Q3 FY26 10-QJun 30, 2026
Synergy CHC	292	5,493	(2,045)	14.9M	0.1 quarters	Q1 FY26 10-QMar 31, 2026
Cellectar Biosciences	33,994	not reported	(6,010)*	9.5M	5.7 quarters	Q2 FY26 10-QJun 30, 2026
X4 Pharmaceuticals	195,095	2,400	(20,788)*	99.1M	9.4 quarters	Q2 FY26 10-QJun 30, 2026
Akari Therapeutics	7,694	not reported	(3,109)*	155.8B	2.5 quarters	Q2 FY26 10-QJun 30, 2026
ProPhase Labs	20	1,011	(78)*	15.6M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Pluri	3,529	335*	(4,443)*	12.3M	0.8 quarters	Q4 FY26 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.